Médecine

Paramédical

Autres domaines


S'abonner

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides - 24/04/13

Doi : 10.1016/j.jaad.2007.12.014 
Putao Cen, MD a, Madeleine Duvic, MD b, c, Philip R. Cohen, MD b, c, d, Razelle Kurzrock, MD a,
a Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 
b Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 
c Department of Dermatology, University of Texas-Houston Medical School, Houston, Texas 
d University of Houston Health Center, Houston, Texas 

Reprint requests: Razelle Kurzrock, MD, Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, MD Anderson Cancer Center, Box 455, PO Box 301402, Houston, TX 77030.

Abstract

Background

Mycosis fungoides, also called cutaneous T-cell lymphoma, comprise a group of extranodal, indolent non-Hodgkin’s lymphomas of T-cell origin with primary involvement of the skin. There are few data available on tumor markers in these patients. Cancer antigen 27.29 (CA27.29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer.

Objective

We sought to assess whether CA27.29 levels were increased in patients with cutaneous T-cell lymphoma and whether there was a correlation of this marker with tumor response.

Methods

We evaluated the CA27.29 blood levels from 6 patients with advanced mycosis fungoides (who had no evidence of breast cancer) and reviewed their charts for information about history and physical examinations, laboratory data, pathology findings, and radiologic examinations.

Results

We demonstrated that 3 of 6 patients with advanced mycosis fungoides had markedly elevated CA27.29 blood levels. In the two patients who had serial blood levels drawn, CA27.29 increased or decreased during treatment as the disease progressed or responded, respectively.

Limitations

This study reflects pilot data on a limited number of patients.

Conclusions

Our observations suggest that CA27.29 merits further investigation as a tumor marker in patients who have cutaneous T-cell lymphoma.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : CA27.29, CHOP, CMED, CTCL, FDA, MF, sMUC1


Plan


 Supported in part by grant RR024148 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from overview-translational.asp.
 Conflicts of interest: None declared.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 58 - N° 3

P. 382-386 - mars 2008 Retour au numéro
Article précédent Article précédent
  • Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features
  • Michelle Heath, Natalia Jaimes, Bianca Lemos, Arash Mostaghimi, Linda C. Wang, Pablo F. Peñas, Paul Nghiem
| Article suivant Article suivant
  • Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial
  • Merete Hædersdal, Katrine Togsverd-Bo, Stine Regin Wiegell, Hans Christian Wulf

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.